Efficacy and safety of long-term treatment with budesonide orodispersible tablets in patients with Eosinophilic Esophagitis - PubMed
6 hours ago
- #Eosinophilic Esophagitis
- #Budesonide
- #Maintenance Therapy
- Budesonide orodispersible tablets (BOT) are effective and safe for long-term treatment of Eosinophilic Esophagitis (EoE).
- The study involved 104 patients treated with BOT (2 mg/day induction, 1 mg/day maintenance) over a 1-year follow-up.
- At 12 weeks (T1), 97.8% of patients achieved histologic remission, and 70.3% maintained remission at 52 weeks (T2).
- Higher Symptom Dysphagia Index (SDI) during induction and maintenance predicted loss of histologic remission at T2.
- BOT-PPI co-administration during maintenance therapy increased the probability of histological response at T2 (OR: 7.8).
- Erosive esophagitis (EE) incidence increased after induction (2.2% vs 13.0%), with BOT-PPI co-administration being protective (OR: 0.14).
- Local candidiasis was the most common adverse event, with risk factors including GERD history, EoE family history, and oral allergy syndrome.
- Clinical monitoring with SDI may help guide maintenance therapy and follow-up timing.